Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dalcetrapib (RO4607381) 是rhCETP 抑制剂(IC50:0.2 μM),具有增加血浆中HDL 胆固醇含量的作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 253 | 现货 | ||
2 mg | ¥ 362 | 现货 | ||
5 mg | ¥ 589 | 现货 | ||
10 mg | ¥ 841 | 现货 | ||
25 mg | ¥ 1,420 | 现货 | ||
50 mg | ¥ 2,160 | 现货 | ||
100 mg | ¥ 3,730 | 现货 | ||
500 mg | ¥ 8,380 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,450 | 现货 |
产品描述 | Dalcetrapib (RO4607381), a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol. |
靶点活性 | CETP (recombinant human):0.2 μM |
体外活性 | Dalcetrapib modulates CETP activity. Dalcetrapib induces a conformational change in CETP, when added to human plasma. CETP-induced pre-β-HDL formation in human plasma is unchanged by Dalcetrapib ≤3 μM and increased at 10 μM. Dalcetrapib statistically and significantly increases pre-β-HDL formation. [1] Dalcetrapib achieves 50% inhibition of CETP activity in human plasma at a concentration of 9 μM. [2] Dalcetrapib inhibits the CETP activity of media in HepG2 in a dose-dependent manner. [3] |
体内活性 | Treatment with Dalcetrapib leads to significant increases in HDL-C levels. In hamsters injected with [3H]cholesterol-labeled autologous macrophages Dalcetrapib significantly increases fecal elimination of both [3H]neutral sterols and [3H]bile acids. Dalcetrapib increases plasma HDL-[3H]cholesterol. [1] Dalcetrapib has 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. Dalcetrapib increases the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 mg/kg or 100 mg/kg once a day for 3 days to male Japanese white rabbits. [2] Treatment with Dalcetrapib markedly increases serum levels of HDL-C. The ratio of HDL2-C to HDL3-C is significantly higher in Dalcetrapib–treated rabbits than in control rabbits at 5 and 7 months, indicating that the inhibition of CETP activity by Dalcetrapib changes the distribution of HDL subfractions and preferentially increases HDL2-C levels. Dalcetrapib treatment increases serum paraoxonase activity and HDL-associated platelet-activating factor acetylhydrolase activity, but decreases the plasma lysophosphatidylcholine concentration. [4] |
激酶实验 | Inhibition of rhCETP and C13S CETP-mediated transfer of CE from HDL to LDL: The inhibitory potency (IC50) of Dalcetrapib to decrease CE transfer from HDL to LDL by rhCETP and C13S CETP is measured using a scintillation proximity assay kit. Briefly, [3H]CE-labeled HDL donor particles are incubated in the presence of purified CETP proteins (final concentration 0.5 μg/mL) and biotinylated LDL acceptor particles for 3 hours at 37 °C. Subsequently, streptavidin-coupled polyvinyltoluene beads containing liquid scintillation cocktail binding selectively to biotinylated LDL are added, and the amount of [3H]CE molecules transferred to LDL is measured by β counting. |
细胞实验 | The HepG2 cells are seeded in 6-well plates and cultured to 70–80% confluence. After being washed with PBS, the cells are incubated with growth medium and a different concentration (0 μM–30 μM) of chemical inhibitor Dalcetrapib and dissolved in 2% DMSO for 24 hours. Total RNA is used for RT-PCR.(Only for Reference) |
别名 | JTT-705, 达塞曲匹, RO4607381 |
分子量 | 389.59 |
分子式 | C23H35NO2S |
CAS No. | 211513-37-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 72 mg/mL (184.8 mM)
Ethanol: 72 mg/mL (184.8 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.5668 mL | 12.834 mL | 25.668 mL | 64.17 mL |
5 mM | 0.5134 mL | 2.5668 mL | 5.1336 mL | 12.834 mL | |
10 mM | 0.2567 mL | 1.2834 mL | 2.5668 mL | 6.417 mL | |
20 mM | 0.1283 mL | 0.6417 mL | 1.2834 mL | 3.2085 mL | |
50 mM | 0.0513 mL | 0.2567 mL | 0.5134 mL | 1.2834 mL | |
100 mM | 0.0257 mL | 0.1283 mL | 0.2567 mL | 0.6417 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dalcetrapib 211513-37-0 Metabolism CETP Inhibitor HDL cholesterol JTT-705 inhibit 达塞曲匹 JTT 705 JTT705 RO 4607381 Cholesteryl ester transfer protein orally active RO4607381 RO-4607381 inhibitor